LivaNova in the news

LivaNova's stock rose 1.81% as the company announced increased full-year 2026 revenue guidance and will report Q3 earnings on November 4.

LivaNova raised its full-year 2026 revenue and EPS guidance after strong Q2 results, with its stock closing at USD 75.07 ahead of its Q3 report.

LivaNova's stock was trading at EUR 66.75 on October 5, 2026, as the company prepares to announce its Q3 2026 results on November 4, 2026, following a strong Q2 performance and raised revenue guidance for the full year.

LivaNova Plc (LIVN) exhibits choppy market conditions with no clear price positioning and elevated downside risk, while AI-generated trading strategies offer risk-managed options.

LivaNova PLC, a UK-based medical technology company, has stock forecasts available following its formation from Cyberonics and Sorin.

LivaNova's stock is perceived as undervalued following a recent pullback, despite strong long-term performance and promising clinical innovations.

LivaNova PLC, a UK company formed from Cyberonics and Sorin, has its stock forecasts being analyzed.

LivaNova's profit outlook is positive due to new product launches, expanded Vagus Nerve Stimulation therapy indications, a cloud-connected digital platform, and expected margin expansion.

LivaNova PLC, a medical device company, shows strong growth potential with innovative products in cardiopulmonary and neuromodulation, backed by positive analyst ratings and solid financials.

LivaNova stock shows stability with recent financial results indicating revenue growth and improved profitability, attracting investor attention to its pipeline in cardiovascular and neuromodulation therapies.

LivaNova granted 6,291 derivative securities to its Chief Legal Officer, Liddy Anne M., on September 15, 2026, representing 100% of her post-transaction holdings.

LivaNova's Chief Legal Officer, Anne M. Liddy, received a grant of 6,291 Restricted Stock Units (RSUs) vesting through 2029.

LivaNova director Francesco Bianchi sold 3,500 shares at $78.01 each on September 10, 2026, reducing his stake by 44.1%.

A LivaNova director sold $273,032 in company stock, while the medical technology company shows strong financials and potential undervaluation.

LivaNova outlined a growth strategy at the Morgan Stanley conference, emphasizing stronger execution in its core cardiopulmonary and epilepsy businesses, and expansion into new markets like obstructive sleep apnea, supported by increased guidance and new product launches.

LivaNova's stock is considered undervalued by analysts, despite a recent share price cooling, driven by clinical innovations and strong future earnings potential.

LivaNova's stock is considered undervalued at $78.18, with a fair value of $89.10, driven by clinical innovations and projected revenue growth.

LivaNova director sold 1,650 shares for $131,500, representing 17% of his direct holdings, while the company continues to develop medical devices in cardiopulmonary and neuromodulation.

LivaNova officer Francesco Bianchi intends to sell 3,500 shares from a 2026 stock award.

LivaNova PLC combines strong growth fundamentals, including robust EPS and revenue increases, with a timely technical setup indicating potential for further upside, despite some financial health caveats.